Matrix metalloproteinase inhibitors to treat tuberculosis
- Summary
- Tuberculosis is an airborne bacterial infection that capitalizes on enzymes produced by the body’s immune system to destroy lung tissue. In particular, the bacteria take advantage of the natural secretion of matrix metalloproteinases (MMPs), which degrade lung tissue and inadvertently facilitate bacterial proliferation. Current tuberculosis treatments consist primarily of antibiotic administration, but are often ineffective in the long term. This technology is an MMP inhibitor that aims to treat tuberculosis by preventing the degradation of lung tissue and subsequent growth of bacteria.
- Technology Benefits
- Reduces lung damage due to tuberculosisHinders proliferation of tuberculosis-causing bacteria in infected tissuePatent Information:Patent Pending (US 20140199289)Tech Ventures Reference: IR 2910
- Technology Application
- Tuberculosis therapyTherapy for patients with antibiotic-resistant tuberculosisTherapy for other diseases in which MMPs are implicated in tissue degradation
- Detailed Technology Description
- None
- *Abstract
-
None
- *Inquiry
- Sara GusikColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- 2910
- *Principal Investigator
-
- *Publications
- Elkington P.T., D’Armiento J.M., Friedland J.S. “Tuberculosis Immunopathology: The Neglected Role of Extracellular Matrix Destruction.” Sci Translational Med. 2011 Feb 23;3(71):71ps6Elkington P.T., Shiomi T., Nuttall R.K, Ugarte-Gil C.A., Walker N.F., Saraiva L., Mauri F., Lipman M., Edwards D.R., Robertson B.D., D’Armiento J.M., Friedland J.S. “MMP-1 Drives Immunopathology in Human Tuberculosis and Transgenic Mice.” J Clin Invest. 2011 May 2;121(5):1827-1833
- Country/Region
- USA
For more information, please click Here
